Figure 5. Immune-sensitized Δ10 3′-UTR ZIKV is effective alone or in combination with anti–PD-1 therapy.

(A) Schematic of Δ10 3′-UTR ZIKV. (B) Mice were implanted with GL261 (n = 14–16) and treated with 10⁶ FFU of Δ10 3′-UTR ZIKV or PBS on day 7 (downward arrow). (C and D) Treatment included Δ10 3′-UTR ZIKV, or PBS as in B, combined with anti–PD-1 or isotype control antibodies administered days 8, 10, 12, and 14, in mice bearing GL261 (n = 9–10) (C) or CT2A (n = 15–16) (D). (E) Survival analysis of mice bearing CT2A glioma cells, treated with Δ10 3′-UTR ZIKV and anti–PD-1 or isotype control antibody as well as anti-CD8 or isotype control antibody as described in the Methods (n = 13–15). Data are pooled from 2 independent experiments. Statistical differences were determined by the log-rank test (**P < 0.01; ***P < 0.001).